Iohexol use while Breastfeeding
Drugs containing Iohexol: Omnipaque 140, Omnipaque 300, Omnipaque 350, Omnipaque 180, Omnipaque 240 Redi-Unit, Omnipaque Flexipak, Omnipaque 240, Myelo-Kit, Omnipaque 180 Redi-Unit, Omnipaque 210
Iohexol Levels and Effects while Breastfeeding
Summary of Use during Lactation
Limited information indicates that maternal doses of iohexol up to 45.3 grams (containing 21 grams of iodine) produce low levels in milk. In addition, because iohexol is poorly absorbed orally, it is not likely to reach the bloodstream of the infant or cause any adverse effects in breastfed infants. Guidelines developed by several professional organizations state that breastfeeding need not be disrupted after a nursing mother receives a iodine-containing contrast medium.[1][2][3]
Drug Levels
Maternal Levels. Four mothers who were 1 week to 14 months postpartum received iohexol by rapid intravenous injection. Three received a dose of 50 mL (37.8 grams; 17.5 grams of iodine) and one received 60 mL (45.3 grams; 21 grams of iodine). Milk samples of 10 mL were collected 9 times over the 48 hours after the injection. The average iohexol milk concentration over the first 24 hours was 24.6 mg/L in the 3 women 1 week to 4 months postpartum and 130.5 mg/L in the one woman who was 14 months postpartum and weaning her infant. The authors calculated that the average amount of iohexol received by the first 3 infants over the first 24 hours would be 3.7 mg/kg or 0.5% of the weight-adjusted maternal dosage.[4]
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Possible Effects on Lactation
Relevant published information was not found as of the revision date.
Alternate Drugs to Consider
References
1. American College of Radiology Committee on Drugs and Contrast Media. Administration of contrast media to breast-feeding mothers. In, ACR manual on contrast media. 2012;Version 8:79-80.
2. Webb JA, Thomsen HS, Morcos SK et al. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005;15:1234-40. PMID: 15609057
3. Chen MM, Coakley FV, Kaimal A, Laros RK Jr. Guidelines for computed tomography and magnetic resonance imaging use during pregnancy and lactation. Obstet Gynecol. 2008;112:333-40. PMID: 18669732
4. Nielsen ST, Matheson I, Rasmussen JN et al. Excretion of iohexol and metrizoate in human breast milk. Acta Radiol. 1987;28:523-6. PMID: 2960342
Iohexol Identification
Substance Name
Iohexol
CAS Registry Number
66108-95-0
Drug Class
- Contrast Agents
- Diagnostic Agents
Administrative Information
LactMed Record Number
527
Information from the National Library of Medicine's LactMed Database.
Last Revision Date
2012-08-31
Disclaimer
Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
See Also...
- Iohexol use during Pregnancy
- Breastfeeding Support Group
- Safe Medications during Breastfeeding
- Medicine use while Breastfeeding
- Medicine use during Pregnancy
Disclaimer: This information is not intended as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. Use of this website signifies your agreement to the Terms of Use and Online Privacy Policy.
